1
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Boehringer Ingelheim International, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, DAVIS Steven G, November 5, 2009: WO/2009/134400 (46 worldwide citation)

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, lo1, lo2, lo5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibit ...


2
Himmelsbach Frank, Claremon David A, Zhuang Linghang, Leftheris Katerina, Xu Zhenrong, Tice Colin M: Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1. Boehringer Ingelheim International, Vitae Pharmaceuticals, Himmelsbach Frank, Claremon David A, Zhuang Linghang, Leftheris Katerina, Xu Zhenrong, Tice Colin M, Abelleira Susan M, January 28, 2010: WO/2010/011314 (37 worldwide citation)

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibit ...


3
Claremon David A, He Wei, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Zhao Wei, Zhuang Linghang, Cacatian Salvacion, Leftheris Katerina: Cyclic inhibitors of 11β-hydroxysteriod dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, He Wei, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Zhao Wei, Zhuang Linghang, Cacatian Salvacion, Leftheris Katerina, DAVIS Steven G, February 5, 2009: WO/2009/017664 (33 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modu ...


4
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, Eckhardt Matthias: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Boehringer Ingelheim International, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, Eckhardt Matthias, DAVIS Steven G, November 5, 2009: WO/2009/134392 (28 worldwide citation)

This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in m ...


5
Xu Zhenrong: Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Vitae Pharmaceuticals, Xu Zhenrong, DAVIS Steven G, February 5, 2009: WO/2009/017671 (27 worldwide citation)

Disclosed are syntheses of 11 β-HSDl inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascul ...


6
Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei: Cyclic urea inhibitors of 11β -hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei, DAVIS Steven G, May 14, 2009: WO/2009/061498 (27 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih)1 (Ij), (Ik), (II1-3). (Im1-3), (In1-3), (lo1-2), (Ip1-6), (Iq1-6), (Ir1-6) and (Is1-2), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful fo ...


7
Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei: Cyclic urea inhibitors of hb-hydroxysteroid dehydrogenase 1. Vitae Pharmaceutical, Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei, DAVIS Steven G, June 18, 2009: WO/2009/075835 (23 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The inve ...


8
Claremon David A, Zhuang Linghang, Ye Yuanjie, Singh Suresh B, Tice Colin M, Xu Zhenrong, Simpson Robert D: Lactam inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Ye Yuanjie, Singh Suresh B, Tice Colin M, Xu Zhenrong, Simpson Robert D, DAVIS Steven G, July 16, 2009: WO/2009/088997 (23 worldwide citation)

This invention relates to novel compounds of the Formula (I), (I*), (Ia), (Ib), (Ic), (Id), (Ie), (If), (If*), (Ig), (Ih), (Ij), (Ik), (ll1-3), (Im1-3), (In1-3), (lo1-2), (Ip1-9), (Iq1-9), (Ir1-9) and (Is1-3) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which a ...


9

10
Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, Wery Jean Pierre: Diaminoalkane aspartic protease inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, Wery Jean Pierre, DAVIS Steven G, April 20, 2006: WO/2006/042150 (13 worldwide citation)

Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the ...